INIBIO
Founded in December 2017, INIBIO has rapidly emerged as a trailblazer in the biopharmaceutical industry. With a young and dynamic team boasting an average age of 31.5 years, the company has achieved significant milestones in a remarkably short period. INIBIO’s swift progress underscores its commitment to innovation and excellence in
biopharmaceutical development.
One of INIBIO’s early achievements was the completion of its own cGMP compliant factory within four years of its establishment. This state-of-the-art facility enabled the company to manufacture its first product, a botulinum toxin type A injection, which received Korean product approval. This achievement laid a strong foundation for INIBIO’s future growth
and product offerings.
INIBIO is quickly expanding into global markets based on high-quality products and localization strategies. Building on this foundation, INIBIO is dedicated to continuous research and development to create patient-friendly and efficient products. The company aims not only to introduce new products but also to advance its proprietary technologies.
By investing in the development of a variety of products, INIBIO seeks to enhance patient care and establish itself as a leader in biopharmaceutical innovation.
- For more information, visit: http://www.inibio.com/
